Clinical Trial Update: FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing 3 months versus 6 months of FOLFOX-4 with Bevacizumab as adjuvant therapy for stage II/III colon cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOX-4

Snippet

Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Conditions: Colon Cancer | Phase 3 | Status: COMPLETED